<DOC>
	<DOCNO>NCT02992652</DOCNO>
	<brief_summary>- The investigator evaluate role allopurinol prevention post-ERCP pancreatitis . - 100 Egyptian patient candidate ERCP include divide two group . Group 1 ( study group ) include 50 patient receive two dos allopurinol 300 mg , 15 hour 3 hour ERCP Group 2 ( control group ) include 50 patient receive allopurinol prophylaxis .</brief_summary>
	<brief_title>Allopurinol Prevention Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis</brief_title>
	<detailed_description>A diagnosis procedure-related pancreatitis base increase serum amylase level great three time upper normal limit , associate abdominal pain require analgesic persist least 24 hour procedure .</detailed_description>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>Patients go subjected ERCP due different cause Patients clinically evident acute pancreatitis hyperamylesemia ( â‰¥150 IU/L ) procedure . Current recent use allopurinol ( within last 48 hour ) . Hypersensitivity allopurinol hydrosoluble contrast solution . Current use drug know interaction allopurinol , include cyclophosphamide , chlorpropamide , azathioprine , mercaptopurine , probenecid . NSAIDS intake within week prior assessment . Previous endoscopic surgical sphincterotomy . Those severe comorbid condition . Female patient know suspected pregnancy and/or lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>